A randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of booster vaccination against ancestral and novel variants of SARS-CoV-2
Latest Information Update: 20 Sep 2023
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; NVX CoV 2373 (Primary) ; Tozinameran (Primary) ; VLA 2001 (Primary) ; Zorecimeran (Primary) ; Aluminium hydroxide; CpG; Matrix M; Meningococcal vaccine groups A C Y W-135 conjugate
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms Cov-Boost
- 19 Apr 2023 Results of 8-month analysis (n=817) comparing the immunogenicity and kinetics of responses to third doses of vaccines from day 28 to day 242 following third doses in seven study arms, published in the Journal of Infection.
- 18 Jan 2023 According to Novavax media release, the company announced that the partner SK biosciences has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for NVX-CoV2373 for use as a booster for active immunization to prevent COVID-19 in adults aged 18 and older. The approval was based on the data from this study.
- 29 Nov 2022 According to a Novavax media release, based on supportive data from this trial, the WHO has issued an updated Emergency Use Listing (EUL) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.